Diabetes drug lowers risk of heart attack, stroke
A glucose-lowering drug has been shown to safely lower the overall risk of heart attack, stroke or cardiovascular death among type 2 diabetes patients.
Patients who were at risk for cardiovascular disease were found to have a 13% lower risk of cardiovascular death, non-fatal heart attack or non-fatal stroke when they took the drug Liraglutide compared to those who took placebo.
The randomised, double-blind study assigned patients either liraglutide or placebo and followed them for an average of 3.8 years.
Study results found a 22% lower risk of cardiovascular mortality, 15% risk of all-cause mortality and 22% lower risk of new evidence of advanced diabetic kidney disease.
“It is exciting to see such a broad-based benefit for patients who took liraglutide because most prior trials of diabetes medications have not shown such benefits,” lead investigator John B. Buse from the University of North Carolina School of Medicine said.
“Our results should give patients and providers comfort that liraglutide can safely improve outcomes beyond the core treatment of type 2 diabetes.”
The results were presented at the American Diabetes Association’s 76th Scientific Sessions in New Orleans over the weekend and were published in the New England Journal of Medicine.
In another study presented published in NEJM, it was found that empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes at high risk for cardiovascular event.